论文部分内容阅读
目的:探讨紫杉醇联合奈达铂治疗非小细胞肺癌的临床疗效。方法:选取我院接受的60例行紫杉醇联合奈达铂治疗的非小细胞肺癌患者作为本次的研究对象,并对其临床资料进行回顾性分析。结果:本组60例患者中9例患者完全缓解,25例患者为部分缓解,19例患者为无变化,7例患者为进展,其总有效率为56.7%;患者的主要毒副反应有血小板下降、恶心、呕吐、肾功能损害、白细胞下降、血色素减少等,患者均未发生肝脏、心脏等损害。结论:给予非小细胞癌患者紫杉醇联合奈达铂治疗可取得良好的治疗效果,且毒副反应低,具有较高的应用价值,可推广应用。
Objective: To investigate the clinical efficacy of paclitaxel combined with nedaplatin in the treatment of non-small cell lung cancer. Methods: Sixty patients with non-small cell lung cancer treated with paclitaxel plus nedaplatin in our hospital were selected as the study subjects and their clinical data were retrospectively analyzed. Results: Nine of 60 patients in this group were completely relieved, 25 patients were partially relieved, 19 patients had no change, 7 patients progressed, and the total effective rate was 56.7%. The main side effects were platelet Decreased, nausea, vomiting, renal dysfunction, leukopenia, hemoglobin decreased, patients did not occur liver, heart and other damage. Conclusion: Paclitaxel combined with nedaplatin in patients with non-small cell carcinoma can achieve good therapeutic effect and low toxic and side effects, which has high value of application and can be widely applied.